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INTRODUCTION:  Neuroendocrine  tumors  (NET)  are a heterogeneous  group  of  rare  carcinomas  that  most
often  manifest  along  the  gastrointestinal  tract. Some  of these  tumors  have  the  ability  to secrete  vasoactive
peptides  and  hormones.
PRESENTATION  OF  CASE:  The  present  report  describes  the case  of a  previously  healthy  52-year  old  man
who presented  with  a painful  right  inguinal  mass.  Upon  surgical  exploration,  a lymph  node  metastasis
of  a high-grade  NET  was  found.  Further  investigations  revealed  a rectal  NET  with  pulmonary,  pelvic  and
penile metastases.
The  patient  was  treated  with  6 cycles  of  carboplatin  and  etoposide.  Although  initial  follow-up  imaging
after  3 cycles  of  chemotherapy  revealed  stable  disease,  there  was  progression  of the  metastases  after
completion  of systemic  treatment.  Second  and  third-line  chemotherapy  regimens  were  instituted  along
with pelvic  and  whole-brain  radiation  therapy  extending  the  patient’s  survival  to 18  months  after  the
initial  diagnosis.
DISCUSSION:  This  case  highlights  the  aggressive  nature  high-grade  NETs  as described  in the  current  lit-
erature.  Treatment  modalities  of  colorectal  NETs  include  local  excision  for non-metastatic  disease  and
systemic  palliative  chemotherapy  for advanced  disease.  However,  there  are  no controlled  trials  in favor
of palliative  chemotherapy.
CONCLUSION: Rectal  NETs  are  rare  tumors  which  often  have  an atypical  presentation  or  present  in
advanced  stages.  Currently,  surgical  options  exist  for  local  disease  while  treatment  modalities  for  more
advanced  disease  is still under  investigation.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Neuroendocrine tumors (NETs) are carcinomas that can arise
nywhere in the body with most reported cases occurring along
he gastro-intestinal tract. NETs represent a heterogeneous group
f malignancies that, in certain cases, exhibit secretory properties,
roducing a variety of vasoactive peptides and hormones, such as
erotonin, histamine, kinins and prostaglandins. They are rare in
omparison to most other neoplasms, representing only 0.9% of all
umors and 2% of gastro-intestinal malignancies [1]. Historically,
hese tumors were referred to as carcinoids. However, the litera-
ure has progressively distanced itself from this nomenclature as
nly a minority of NETs displays the classic presentation of car-
inoid syndrome (ﬂushing, diarrhea and heart failure) [1,2]. This
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article reviews the case of a patient with a metastatic rectal NET
that initially presented as a painful inguinal mass.
2. Presentation of case
A 52 year-old male patient presented to the emergency depart-
ment with right groin pain for 1 week that began after strenuous
activity. On physical exam, there was  a ﬁrm non-reducible right
inguinal mass. The patient had no symptoms of bowel obstruction
and abdominal examination was  unremarkable. No other com-
plaints were formulated by the patient at that time. Complete blood
count and serum creatinine and electrolytes were all within nor-
mal  values. The differential diagnosis included an incarcerated right
inguinal or femoral hernia or a right inguinal lymphadenopathy.
As an uncomplicated non-reducible inguinal hernia was  the pri-
mary diagnosis at the time, an open right groin exploration was
performed 2 days later without preoperative imaging.
On surgical exploration, no inguinal or femoral hernia was
detected. However, a mobile, indurated 2.5 cm right inguinal mass
was found and an excisional biopsy of the entire mass was per-
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Ulcerated lesion of the rectum found at endoscopy (black arrow).
Fig. 2. CT of the chest showing multiple bilateral lung nodules (white and black
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Fig. 3. CT of the pelvis showing multiple peri-rectal nodules (white arrows).
intestinal system. Although they can present anywhere along the
alimentary tract, rectal NETs are most common, representing 17.7%rrows).
ormed. Had preoperative ultrasound or computed tomography
maging been obtained, a percutaneous biopsy could have been
arried out, albeit with the risk of insufﬁcient tissue sampling.
reliminary microscopic evaluation determined the mass to be a
ymph node metastasis with capsular invasion of an undifferen-
iated carcinoma of possible uro-genital origin. No lymphocytic
roliferation was noted, excluding the possibility of lymphoma.
On further physical examination, the patient was noted to have
hree 0.5 cm subcutaneous nodules at the base of the penis and an
ndurated lesion extending 5 cm up from the anal verge on digi-
al rectal exam. On colonoscopic investigation, an ulcerated lesion
n the right rectal wall extending 4 cm up from the anal verge was
ound along with a submucosal nodule that was tentatively thought
o be a lymph node (see Fig. 1). Endoscopic biopsies of the lesion
ere performed. Pathological diagnosis was that of a high-grade
euroendocrine carcinoma with keratin-7, chromogranin A and
ynaptophysin enhancement. Ki67 study showed a proliferation
ndex of 80%.
Serum chromogranin A was elevated (114.0 ng/mL), as well
s carcinoembryonic antigen (13.8 g/L) and CA 19-9 (92 kU/L).
wenty-four hour urinary excretion of 5-HIAA was normal.
Computed tomography (CT) of the chest, abdomen and pelvis
howed bilateral lung nodules measuring up to 1.4 cm and multi-
le peri-rectal nodules up to 2.3 cm in diameter (see Figs. 2 and 3).
agnetic resonance imaging (MRI) of the pelvis demonstrated an
no-rectal tumor extending 5.5 cm from the anus with invasion of
he levator ani muscle and satellite nodules at the base of the penis
nd in the peri-rectal fat (see Fig. 4). Positron-emitting tomogra-
hy conﬁrmed the hypermetabolic and metastatic nature of all the
forementioned lesions.Fig. 4. Sagittal view of pelvic MRI  showing rectal mass with invasion of levator
ani muscle and satellite nodules of the peri-rectal fat and base of the penis (white
arrows).
The patient began complaining of ano-rectal pain as well as
occasional blood per rectum. The patient agreed to palliative
chemotherapy and a 6-cycle regimen of carboplatin and etopo-
side was  started. The patient tolerated the treatment with the
exception of transient afebrile neutropenia that delayed the ﬁnal
treatment by one week. The peri-rectal pain resolved completely
with chemotherapy and CT of the chest, abdomen and pelvis after 3
cycles of chemotherapy showed stable disease. Follow-up CT after
6 cycles showed progression of the lung and peri-rectal metastases
and a new large celiac trunk lymph node metastasis (3 cm).
The patient was  then switched to a 12-cycle regimen of FOLFIRI,
of which he received only 11 cycles due to hepatic toxicity and 2
cycles of topotecan. However, follow-up imaging showed progres-
sion of the lung and intra-abdominal lymph node metastases and
multiple new cerebral and hepatic lesions. The patient went on
to receive intensity-modulated radiation therapy to the pelvis (for
ano-rectal pain and disease progression) and whole-brain radiation
therapy.
Disease progression and the patient’s general deterioration led
to a discontinuation of chemotherapy and institution of comfort
measures. The patient died 18 months after the initial diagnosis.
3. Discussion
As previously mentioned, NETs are a rare entity representing
less than 1% of all cancers, with a preponderance for the gastro-of all NETs according to one American survey [1,3]. The vast major-
ity of rectal NETs are non-secreting and can be either low-grade,
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ndolent malignancies (often discovered on routine endoscopy
tudies) or high-grade tumors, which can be aggressive in nature
ith high metastatic potential [4]. Overall, colorectal NETs are often
iagnosed at an advanced stage. One series reported 66% of newly
iscovered colorectal NETs were metastatic at the time of presen-
ation [5]. This ﬁgure is relatively high because of right-sided colic
ETs that are often clinically silent.
Low-grade rectal NETs are amenable to either endoscopic
r surgical local excision and often do not respond to sys-
emic chemotherapy. A variety of surgical procedures have been
escribed for lesions too large to be removed endoscopically. These
nclude a low anterior resection, abdomino-perineal resection or
rans-anal endoscopic micro-surgery (TEMS). Recurrence after each
f these surgical interventions is rare if negative margins are
btained [1,6].
Pathological diagnosis of NETs is important as treatment reg-
mens differ greatly from the more common gastro-intestinal
eoplasms. Ki67 staining assesses the proliferation rate of the
eoplastic cells [7]. Higher-grade lesions, especially if metastatic
n nature, will often respond, at least transiently, to a platinum-
ased chemotherapy regimen. Although no randomized controlled
rials studied the effect chemotherapy on colorectal NETs, regi-
ens combining carboplatin or cisplatin with etoposide are usually
mployed, based on their use in other advanced NETs or small-cell
ung carcinoma, a pathologically similar entity [8,9]. There is cur-
ently no role for the surgical management of advanced metastatic
olorectal NETs albeit for palliation in the case of bowel obstruction,
ain or bleeding [9].
Targeted therapies for NETs are developing. Preliminary stud-
es have shown that the use of tyrosine-kinase inhibitors such as
unitinib or mTOR inhibitors (everolimus) may  confer a survival
dvantage in well-differentiated pancreatic NETs. No trials have
et studied their effect on colorectal NETs [10,11].
Gastro-intestinal NETs tend to metastasize in characteristic pat-
erns following the lymphatic drainage of their anatomic location.
ntestinal and colic NETs will metastasize to the mesenteric lymph
odes and to the liver. Furthermore, ano-rectal NETs can spread
o pelvic and inguinal lymph nodes and tend to bypass the liver
nd present with metastatic disease to the lung, as observed in the
resent case [1,9].
In comparison to rectal adenocarcinoma, NETs generally have
 poorer prognosis. However, even high-grade tumors remain
elatively indolent, as metastatic colorectal NETs have a 2-year sur-
ival of 80% [12]. One study of 8 patients receiving cisplatin and
toposide for metastatic colorectal NETs demonstrated a median
rogression-free survival of only 4.5 months and a median overall
urvival of 9.5 months [8].
. Conclusion
Rectal NETs are uncommon tumors with often atypical presen-
ation or an incidental discovery at endoscopy. Most are diagnosed
t an advanced stage with the tumor showing many high-grade fea-
ures and already metastatic. Pathologic diagnosis is important as
reatment is different from the much more common rectal adeno-
arcinoma. Although early stage tumors can be resected, treatment
f more advanced disease is systemic palliative chemotherapy.
o controlled studies have demonstrated survival advantage of
hemotherapy although there is a trend in progression-free sur-
ival in certain series.
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